HROW241220P44000
- 0.00
- 0.000.00%
Harrow Newsroom
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Cuts Target Price to $69
Express News | Harrow Inc : B. Riley Cuts Target Price to $69 From $73
10 Health Care Stocks With Whale Alerts In Today's Session
Harrow Says ImprimisRx Unit Wins Jury Verdict in Trademark Infringement Case
Express News | Harrow’s Imprimisrx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in Imprimisrx, LLC V. Osrx, Inc.
Express News | Harrow Inc - Melt-300 Shows Statistical Superiority Over Midazolam and Placebo
Express News | Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for Melt-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
Lake Street Initiates Harrow(HROW.US) With Buy Rating, Announces Target Price $55
Harrow Health's Strategic Transformation and Growth Potential Underscore Buy Rating
US Manufacturing Index Rises To 43, Highest Since 2020
Harrow Announces Participation in Upcoming Investor Conferences
Harrow Inc. Reports Strong Q3 2024 Growth
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript Summary
Harrow Down Nearly 13%, on Pace for Largest Percent Decrease Since November 2023 -- Data Talk
Express News | Harrow Shares Down 18% After Q3 Revenue Misses Estimate
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $55
Wall Street Set to Open Flat Thursday; Initial Jobless Claims Lower Than Forecast